Related references
Note: Only part of the references are listed.Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Robert H. Jones et al.
LANCET ONCOLOGY (2020)
Role of Akt Activation in PARP Inhibitor Resistance in Cancer
Ferenc Gallyas et al.
CANCERS (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*
Christine I. Chen et al.
LEUKEMIA & LYMPHOMA (2019)
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
N. C. Turner et al.
ANNALS OF ONCOLOGY (2019)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study
Brittany Knick Ragon et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Y-J Bang et al.
EUROPEAN JOURNAL OF CANCER (2019)
First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma
Chiara Leoni et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2019)
The relation between PI3K/AKT signalling pathway and cancer
Saeed Noorolyai et al.
GENE (2019)
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer
Joyce F. Liu et al.
GYNECOLOGIC ONCOLOGY (2019)
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
M. Oliveira et al.
ANNALS OF ONCOLOGY (2019)
Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
Toshihiko Doi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Akt in cancer: Mediator and more
Sundaramoorthy Revathidevi et al.
SEMINARS IN CANCER BIOLOGY (2019)
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Jeeyun Lee et al.
CANCER DISCOVERY (2019)
The PTEN-PI3K Axis in Cancer
Antonella Papa et al.
BIOMOLECULES (2019)
MALAT1 promotes gastric adenocarcinoma through the MALAT1/miR-181a-5p/AKT3 axis
Zhengmao Lu et al.
OPEN BIOLOGY (2019)
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2-Metastatic Breast Cancer: Biological Mechanisms and New Treatments
Daniele Presti et al.
CANCERS (2019)
Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
Nicola Bougen-Zhukov et al.
CANCERS (2019)
Overview of the relevance of PI3K pathway in HR-positive breast cancer
N. Vasan et al.
ANNALS OF ONCOLOGY (2019)
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
M. Brandao et al.
ANNALS OF ONCOLOGY (2019)
Targeted Therapies for Triple-Negative Breast Cancer
Tomas G. Lyons
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
Antonio Pellino et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Sarah P. Blagden et al.
CLINICAL CANCER RESEARCH (2019)
Targeting PI3K Signaling in Acute Lymphoblastic Leukemia
Vanessa Edna Sanchez et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study
Shannon N. Westin et al.
GYNECOLOGIC ONCOLOGY (2019)
Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
Kim M. Keppler-Noreuil et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2019)
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
Jack J. Chan et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Clinical Implementation of Precision Medicine in Gastric Cancer
Jaewook Jeon et al.
JOURNAL OF GASTRIC CANCER (2019)
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Ricardo L. B. Costa et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The Strategy of PIKing a Target: What Is AKTually Most Effective?
Carlotta Costa et al.
CLINICAL CANCER RESEARCH (2018)
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Carol Aghajanian et al.
INVESTIGATIONAL NEW DRUGS (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?
Vincent Pretre et al.
SEMINARS IN CANCER BIOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER plus endometrial or ovarian cancer
David Hyman et al.
CANCER RESEARCH (2018)
Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania
Devki Nandan et al.
PLOS ONE (2018)
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2018)
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J. Arceci et al.
PEDIATRIC BLOOD & CANCER (2017)
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura et al.
CANCER DISCOVERY (2017)
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M. Hyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
Maximising the potential of MKT inhibitors as anti-cancer treatments
Jessica S. Brown et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Development of PD-1/ PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes
Ian Chau
CLINICAL CANCER RESEARCH (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Akt as a target for cancer therapy: more is not always better (lessons from studies in mice)
Qi Wang et al.
BRITISH JOURNAL OF CANCER (2017)
Recent progress towards clinically relevant ATP-competitive Akt inhibitors
Bayard R. Huck et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
AKT in cancer: new molecular insights and advances in drug development
Prabhjot S. Mundi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
Kenji Tamura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway
Sai-Qi Wang et al.
ONCOTARGET (2016)
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Sherri Z. Millis et al.
JAMA ONCOLOGY (2016)
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
Paul Toren et al.
EUROPEAN UROLOGY (2015)
PI3K and AKT: Unfaithful Partners in Cancer
Seraina Faes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer
Mei Yang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yi Yu et al.
PLOS ONE (2015)
PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn J. X. Lee et al.
CANCER BIOLOGY & MEDICINE (2015)
Signalling specificity in the Akt pathway in breast cancer
Abbe R. Clark et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer et al.
BLOOD (2014)
HER2 Expression and PI3K-Akt Pathway Alterations in Gastric Cancer
Yasutaka Sukawa et al.
DIGESTION (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
Tasuku Matsuoka et al.
CANCERS (2014)
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin et al.
CLINICAL CANCER RESEARCH (2013)
Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Yibing Yan et al.
CLINICAL CANCER RESEARCH (2013)
Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil
Zhengdeng Lei et al.
GASTROENTEROLOGY (2013)
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
Jing Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN
Shou-mei Yang et al.
TOXICOLOGY (2013)
Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
James F. Blake et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
Didier Roulin et al.
MOLECULAR CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
David A. Guertin et al.
CANCER CELL (2009)
The Akt kinases Isoform specificity in metabolism and cancer
Eva Gonzalez et al.
CELL CYCLE (2009)
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
M. S. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Activated Akt as an indicator of prognosis in gastric cancer
Caterina Cinti et al.
VIRCHOWS ARCHIV (2008)
Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy
Daiki Murakami et al.
GASTRIC CANCER (2007)
Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma
Iwao Kobayashi et al.
PATHOBIOLOGY (2006)
Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas
Young Hwa Soung et al.
ONCOLOGY (2006)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
Akt/PKB-activation in gastric carcinomas correlates with clinicopathologic variables and prognosis
SY Nam et al.
APMIS (2003)
Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families
PDP Pharoah et al.
GASTROENTEROLOGY (2001)
Share Paper
